GFAP and Dyskinesia: In Parkinson’s disease mouse models, the oral administration of the 4b analogue improved dyskinesia, reduced the expression of glial fibrillary acidic protein (GFAP; a marker of neuroinflammation) and increased a number of tyrosine hydroxylase-positive cells [83].